PER 10.5% 7.4¢ percheron therapeutics limited

“Notably, Sarepta aims to broaden use of Elevidys to include...

  1. 13,150 Posts.
    lightbulb Created with Sketch. 1380
    “Notably, Sarepta aims to broaden use of Elevidys to include patients who can no longer walk, a group whose disease is more advanced. That request “is more of a stretch,” Lugo wrote. “We would not be surprised if these patients are excluded from the expanded label.”
    ——————————/
    Does that mean Non Ambulant DMD people won’t be able to access Elevidys ?
    Leaves the door open for Atl 1102 to work its magic
    Imo: FDA will do as Lugo wrote ..
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.4¢
Change
0.007(10.5%)
Mkt cap ! $66.71M
Open High Low Value Volume
6.5¢ 7.5¢ 6.3¢ $91.29K 1.309M

Buyers (Bids)

No. Vol. Price($)
1 49999 7.4¢
 

Sellers (Offers)

Price($) Vol. No.
7.8¢ 75476 2
View Market Depth
Last trade - 16.10pm 06/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.